Non-Cirrhotic Non-Alcoholic Steatohepatitis

Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis

NASH is a liver disease associated with inflammation and liver cell injury visible under a microscope with a liver biopsy. This condition may lead to advanced scarring of the liver called fibrosis and cirrhosis and deserves serious medical management. NASH might also lead to liver cancer. At this time, there are no drugs approved for the treatment of NASH. Napa Research has a clinical research study aimed at improving your liver tissue scars (fibrosis) and potentially resolving NASH using the study medication.

Mode of administration:

Tablets taken orally

The study duration: 5-7 Years

Participants will attend 22 study site visits, 13 phone calls visits and receive follow-up checks following the completion of the study.

Compensation package includes:

$150.00 per completed visit.

$500.00 for liver biopsy.

$75.00 for Fibroscan

All study medication, assessments and examinations are free to the participants.

Inclusion Questions:

Has the patient ever been diagnosed with NASH?

Does the patient have a history of at least 1 unsuccessful attempt to reduce body weight?

Patient’s other medical conditions: